Actionable news
All posts from Actionable news
Actionable news in MYL: Mylan Inc.,

How Mylan Plans to Leverage Its Meda Acquisition

What Factors Are Driving Mylan's Valuations in 2016?

(Continued from Prior Part)

Leveraging the Meda acquisition

Since Meda derives about half of its total revenue from the respiratory and allergy, dermatology, and pain segments, the combined Mylan–Meda entity is expected to have an enhanced presence in these segments.

Mylan (MYL) also believes that after the acquisition of Meda, the combined company will have six franchises worth $1 billion. These franchises will involve infectious diseases, gastrointestinal diseases, cardiovascular diseases, respiratory and allergy-related ailments, metabolic and diabetes-related conditions, and diseases related to the central nervous system.

How Mylan Plans to Leverage Its Meda Acquisition

The above diagram shows that the acquisition will also help to strengthen Mylan’s position in areas such as pain, anesthesia, women’s health, and dermatology.

Respiratory and allergy segment...